Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, -2, and -3

The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown., Ixekizumab maintenance dosing (12-60-weeks) had a neutral impact on cardiovascular-related parameters (including total cholesterol, LDL-cholesterol, HDL-cholesterol, LDL/HDL, triglycerides), Ixekizumab's neutral impact on cardiovascular-related parameters should not alter decisions to treat with other medications/interventions targeting cardiovascular-related parameters.